Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial

This multicenter phase-II trial aimed to investigate the efficacy, safety, and predictive biomarkers of toripalimab plus chemotherapy as second-line treatment in patients with EGFR-mutant-advanced NSCLC. Patients who failed from first-line EGFR-TKIs and did not harbor T790M mutation were enrolled. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Tao, Wang, Pingyang, Zhang, Jie, Zhao, Yanqiu, Zhou, Jianying, Fan, Yun, Shu, Yongqian, Liu, Xiaoqing, Zhang, Helong, He, Jianxing, Gao, Guanghui, Mu, Xiaoqian, Bao, Zhang, Xu, Yanjun, Guo, Renhua, Wang, Hong, Deng, Lin, Ma, Ningqiang, Zhang, Yalei, Feng, Hui, Yao, Sheng, Wu, Jiarui, Chen, Luonan, Zhou, Caicun, Ren, Shengxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517012/
https://www.ncbi.nlm.nih.gov/pubmed/34650034
http://dx.doi.org/10.1038/s41392-021-00751-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517012/
https://www.ncbi.nlm.nih.gov/pubmed/34650034
http://dx.doi.org/10.1038/s41392-021-00751-9

Ejemplares similares